Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
Trial Details
- NCT ID
- NCT07730515
- Phase
- PHASE1 / PHASE2
- Sponsor
- Evopoint Biosciences Inc.
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- XNW5004 combined with CHOP (incremental)
- XNW5004 combined with CHOEP (incremental)
- XNW5004 combined with CHOP (extended)
- XNW5004 combined with CHOEP (extended)
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Age 18 to 75 years (inclusive); both genders are eligible.
- Pathologically confirmed peripheral T-cell lymphoma (PTCL).
- No prior systemic anti-PTCL therapy.
- At least one measurable lesion as the basis for evaluation: nodal lesions with a long diameter \> 1.5 cm; extranodal lesions with a long diameter \…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →